Pharming Group is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases, primarily focusing on immunological and genetic conditions. The company's commercial portfolio includes two approved therapies: RUCONEST®, a recombinant C1 esterase inhibitor protein replacement therapy for acute hereditary angioedema attacks in adult and adolescent patients, and Joenja®, an oral selective phosphoinositide 3-kinase delta inhibitor for activated phosphoinositide 3-kinase delta syndrome, an ultra-rare primary immunodeficiency. The pipeline encompasses global expansion of leniolisib across additional age groups and patient populations with related primary immunodeficiencies, as well as napazimone for primary mitochondrial disease, a late-stage asset acquired to address a large underserved patient population with no approved disease-modifying treatments. Revenue is generated through commercial sales of these marketed therapies, with the company pursuing disciplined capital allocation focused on markets with specialist care infrastructure, diagnostic readiness, and sustainable reimbursement pathways.